| Market Cap | 466.85M | P/E | - | EPS this Y | -4.70% | Ern Qtrly Grth | - |
| Income | -37.87M | Forward P/E | -6.59 | EPS next Y | 3.00% | 50D Avg Chg | -10.00% |
| Sales | - | PEG | -0.11 | EPS past 5Y | - | 200D Avg Chg | 4.00% |
| Dividend | N/A | Price/Book | 3.41 | EPS next 5Y | 73.70% | 52W High Chg | -33.00% |
| Recommedations | 1.40 | Quick Ratio | 2.91 | Shares Outstanding | 59.42M | 52W Low Chg | 61.00% |
| Insider Own | 2.45% | ROA | -19.11% | Shares Float | 43.13M | Beta | 1.43 |
| Inst Own | 60.19% | ROE | -33.19% | Shares Shorted/Prior | 2.98M/2.92M | Price | 7.97 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,220,874 | Target Price | 10.00 |
| Oper. Margin | - | Earnings Date | Nov 1 | Volume | 486,154 | Change | -0.38% |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Oct 16 | Sell | 1.67 | 2,756,499 | 4,603,353 | 8,593,586 | 10/18/23 |
| Brady Todd C | President and CEO President and CEO | Sep 07 | Option | 0.55 | 273,058 | 150,182 | 1,728,343 | 09/11/23 |
| PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Aug 08 | Buy | 7.24 | 97,000 | 702,280 | 11,235,085 | 08/10/22 |
| PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Aug 04 | Buy | 6.17 | 95,100 | 586,767 | 10,997,085 | 08/08/22 |
| PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Aug 01 | Buy | 5.05 | 144,185 | 728,134 | 10,389,579 | 08/03/22 |
| PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Jul 28 | Buy | 5.00 | 119,392 | 596,960 | 10,023,271 | 08/01/22 |
| JOYCE MARTIN JOSEPH | Director Director | Jun 23 | Buy | 3.4755 | 4,323 | 15,025 | 23,967 | 06/27/22 |
| Brady Todd C | President and CEO President and CEO | Jun 23 | Buy | 3.3642 | 17,700 | 59,546 | 1,216,535 | 06/27/22 |
| - | - - | Jan 11 | Buy | 8.79 | 1,050,000 | 9,229,500 | 7,335,458 | 01/11/21 |